Skip to Content

Acrux Ltd ACR Stock Quote

| Rating as of


Morningstar‘s Stock Analysis ACR

Currency in AUD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics ACR

Company Profile ACR

Business Description

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products which administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution and among others.

103-113 Stanley Street, West Melbourne
Melbourne, VIC, 3003, Australia
T +61 383790100
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2023
Employees 36